BioStem Technologies, Inc. Overview
Pro stress-test →BioStem Technologies is a regenerative biotechnology company focused on harnessing elements of perinatal tissue to develop and manufacture tissue allografts for the wound care market with a focus on treating diabetic, pressure, and venous ulcers. The company utilizes its proprietary BioRetain processing method to manufacture perinatal tissue allografts.
Strategic Profile
Pro stress-test →In January 2026, BioStem acquired the Surgical and Wound Care Business of BioTissue Holdings Inc. for $40 million, with the transaction expected to be accretive to BioStem's growth, EBITDA and profitability in 2026. In April 2026, the company presented at the 25th Annual Needham Virtual Healthcare Conference, highlighting its continued progress in regenerative medicine and expanding portfolio of advanced perinatal tissue allografts.
Competitive Landscape
Pro stress-test →BioStem competes in the regenerative medicine and advanced wound care sector against established players and specialized wound care companies. The company's proprietary BioRetain processing technology and perinatal tissue focus provide differentiation, while the recent BioTissue acquisition strengthens competitive positioning by adding established product lines and commercial infrastructure.
Industry Context
BioStem Technologies, Inc. operates in Biotechnology / Regenerative Medicine / Advanced Wound Care.
Key facts
Founded: 2006 · Headquarters: Pompano Beach, FL · Revenue: $2.5M · Market cap: $74.9M